Cibus (CBUS) Retained Earnings (2016 - 2026)
Cibus (CBUS) posted Retained Earnings of -$858.3 million for Q4 2025, down 197.6% sequentially from $879.4 million in Q3 2025, and down 17.38% YoY from -$1.0 billion in Q4 2024.
Cibus (CBUS) Retained Earnings (2016 - 2026) Analysis & Trends
Cibus has reported Retained Earnings for 10 years, with the latest figure at -$858.3 million in Q4 2025.
- Quarterly Retained Earnings fell 17.38% year-over-year to -$858.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$858.3 million (down 17.38% YoY) and the FY2025 annual result came in at -$858.3 million, down 17.38% from the prior year.
- Retained Earnings fell to -$858.3 million in Q4 2025 per CBUS's latest filing, from $879.4 million in the prior quarter.
- Over five years, Retained Earnings peaked at $879.4 million in Q3 2025 and troughed at -$858.3 million in Q4 2025.
- A 5-year average of $25.6 million and a median of -$185.4 million in 2021 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2021 and 2024: Retained Earnings tumbled 6299900.0% in 2021, then soared 40030400.0% in 2024.
- Over 5 years, Retained Earnings stood at -$196.1 million in 2021, then slipped by 8.19% to -$212.2 million in 2022, then surged by 465.31% to $775.0 million in 2023, then slumped by 194.34% to -$731.2 million in 2024, then retreated by 17.38% to -$858.3 million in 2025.
- According to Business Quant data, Retained Earnings over the past three periods registered -$858.3 million, $879.4 million, and $877.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Cibus | 129.72 Mn | 109.29 Mn | - | 918.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 918.64 Mn |
| Dec 31, 2025 | -858.25 Mn |
| Sep 30, 2025 | 879.38 Mn |
| Jun 30, 2025 | 877.53 Mn |
| Mar 31, 2025 | 27,000.00 |
| Dec 31, 2024 | -731.17 Mn |
| Sep 30, 2024 | 818.21 Mn |
| Jun 30, 2024 | 800.61 Mn |
| Mar 31, 2024 | -17,000.00 |
| Dec 31, 2023 | 775.02 Mn |
| Sep 30, 2023 | -262.66 Mn |
| Jun 30, 2023 | -2,000.00 |
| Mar 31, 2023 | -217.55 Mn |
| Dec 31, 2022 | -212.15 Mn |
| Sep 30, 2022 | -209.31 Mn |
| Jun 30, 2022 | -203.36 Mn |
| Mar 31, 2022 | -200.88 Mn |
| Dec 31, 2021 | -196.09 Mn |
| Sep 30, 2021 | -189.00 Mn |
| Jun 30, 2021 | -181.73 Mn |